Alluvi, formerly LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist https://alluvihealthcare128613.thunkblog.com/662952/alluvi-a-deep-dive-into-retatrutide-s-potential